198 results
SD
EX-1.01
ABBV
Abbvie Inc
31 May 24
Conflict minerals disclosure
4:05pm
supply AbbVie with materials containing 3TG for the Products. AbbVie surveyed the majority of these suppliers, excluding those reporting no 3TG use
8-K/A
ABBV
Abbvie Inc
8 May 24
Departure of Directors or Certain Officers
5:00pm
to implement simple majority voting, as follows:
For
Against
Abstain
Broker Non-Votes
The stockholders did not approve a stockholder proposal to issue
PX14A6G
Chevedden John
26 Mar 24
Letter to shareholders
2:31pm
for Both Simple Majority Vote Proposals, Proposals 5 and 6
The reason to vote for both Simple Majority Vote Proposals is that Proposal 5 is a binding … outstanding, it would result in an astounding 6,000% return ($600 million) on the investment of the 6-figure sum.
The Simple Majority Vote Proposal is so
DEFA14A
ABBV
Abbvie Inc
18 Mar 24
Additional proxy soliciting materials
4:17pm
regarding amendment of the certificate of incorporation to eliminate supermajority voting For 6. Stockholder Proposal – to Implement Simple Majority
8-K
EX-4.3
xqpha1rm kv
26 Feb 24
Other Events
5:08pm
8-K
EX-4.5
09klteye wpwcgsk16kx
26 Feb 24
Other Events
5:08pm
8-K
EX-4.9
i3l2me0brpzp ee
26 Feb 24
Other Events
5:08pm
8-K
EX-4.4
ht4kse
26 Feb 24
Other Events
5:08pm
8-K
EX-4.6
k74lpfm cyold
26 Feb 24
Other Events
5:08pm
8-K
EX-4.7
6a2au6s3or9z40q18t
26 Feb 24
Other Events
5:08pm
8-K
EX-4.8
4z7x ssnvw0b600g
26 Feb 24
Other Events
5:08pm
424B5
wvfc6z9
26 Feb 24
Prospectus supplement for primary offering
6:12am
S-8
EX-4.4
grjk7 a8zrjs4
22 Feb 24
Registration of securities for employees
5:50pm
S-8
EX-4.5
xoem4y fy9ds
22 Feb 24
Registration of securities for employees
5:50pm
424B5
sry7z2vkla2hhjcxk2o5
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
2ia53s
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am